Fresenius Medical Care 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Fresenius Medical Care reported broadly stable third-quarter 2026 revenue and earnings despite anticipated Tedapa reimbursement headwinds and increased inflationary pressures.
- Group revenue was supported by organic growth in care delivery and partly offset by lower value-based care revenue; divestitures reduced group revenue development by 30 basis points.
- Operating income excluding special items declined 6% at constant currency, while the operating income margin was 11%; third-quarter special items were a net negative $161 million.
- FME25 plus generated $74 million of sustainable savings in the quarter, with $64 million of one-time costs; the company remained on track to deliver $250 million of sustainable savings for the full year.
- Care delivery revenue increased 1% at constant currency and 2% organically, while operating income increased 2% at constant currency and the margin expanded to 14.7%. Care delivery operating income excluding Tedapa effects rose 21% year over year.
- US market treatment growth declined 1.1% in the quarter, while international same market treatment growth was 1.4%. Patient inflow in the US stabilized in the third quarter at a level similar to the prior-year quarter.
- Value-based care revenue decreased 9% on both an organic and constant currency basis; operating income excluding special items improved to positive $1 million from a $21 million loss in the prior year.
- Care enablement revenue grew 5% organically and at constant currency, and earnings increased 4%, supported by 5008X momentum and favorable pricing and volumes outside China.
- The 5008X rollout reached 348 clinics, or 14% of clinics, with approximately 9,000 machines installed, or approximately 16% of the install base, by the end of September. About 300,000 treatments in the first nine months reached HVHDF, around 1.3% of total treatments.
- Operating cash flow increased 8% in the third quarter. Net leverage was 2.6 times, and the company had repurchased 3.4% of share capital for $357 million by September 30th under its second $1 billion share buyback program.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, welcome to the report on third quarter 2026 earnings call. I am Valentina, the call's call operator. I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Dominik Heger.
Please go ahead. Thank you, Valentina.
I would like to welcome everyone to our earnings call for the third quarter 2026. As always, I start out the call by mentioning our cautionary language that is in our safe harbor statement, as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. The call is scheduled for 1 hour. In order to give everyone the chance to ask questions, we would limit the number of questions to 2, as always. Thank you for making this work. With us today for the first time is Shervin Korangy, our new CEO and Chair of the Management Board, and of course, Martin Fischer, our Chief Financial Officer.
As Shervin joined Fresenius Medical Care as Fresenius Medical Care CEO 3 weeks ago, Martin will lead more of the discussion today and more of the answers to your questions today. I will now hand over to Shervin for some introductory remarks. Shervin, the floor is yours.
Thank you, Dominik, and welcome everyone. I'm very pleased to be here and to be speaking with you for the first time as the CEO of Fresenius Medical Care. It's been just 3 weeks since I stepped into the role, and I am excited about the opportunity ahead. With this business, I see a collection of market-leading assets, but one that is still being shaped. The last years have laid a nice groundwork, and at the same time, I believe there is much we can refine going forward. This spans from portfolio to execution to how we look at and assess our business. As you know, I've served on the Supervisory Board since December 2023, so I'm coming into the role with some familiarity. But as you can imagine, the depth of understanding needed will take a little bit of time.
We are proceeding with urgency, yet I appreciate a little bit of patience as that process, which I am sure many of you have experienced in other investments in your portfolios or companies you have covered when facing a leadership change. You may be wondering what really excites me about the company. We are a global leader in kidney care. We have capabilities and reach that no other company in our space has access to, nor could build in short order. Yet many parts of our business are still young in their development cycle, given the structural changes of the last few years. That provides opportunity for improvement that can be step change versus a slower progression that more mature businesses face. My focus will be to expand and improve the continuity of care for our patients, which, if done well, will drive long-term profitable growth.
I have spent my first days getting first deep into the business and honing in on the most important value drivers, and second, looking for and assessing both areas of improvement and areas of expansion. I have heard from many stakeholders and welcome continued feedback and perspective, which will help us shape future plans. I am also encouraging the organization to take a longer-term view in developing our plans. We must balance that long-term perspective with critical short-term wins, which will build continued confidence in our organization. Delivering on this balance is a core message to our organization internally. Sustainable success comes from laying thoughtful multi-year plans, but identifying key milestones and metrics that prove the plan is taking shape along the way, so that our shareholders, our supervisory board, and our people can continue to invest in our success.
Looking forward, I am sure you are eager to hear more about my future vision for the company. We will be rolling out our 2027 planning in due course. With that, let me turn to our third quarter results highlights on slide 6 before handing over to Martin to walk through all of the details. As Dominik mentioned, I will keep my comments at a high level. Turning to our third quarter performance, Fresenius Medical Care delivered broadly stable revenue and earnings despite some headwinds. The underlying business performance continued to improve, helping to offset the anticipated reimbursement headwinds coming from TDAPA. You are all aware that the HHS released their kidney care national plan 2 weeks ago. It is to see that many of the priorities outlined in the plan are aligned with our thinking.
Specifically, innovation is critical for this sector, like the recent approval of our multiFiltratePRO product, a needed advancement in the critical care segment, and of course, the U.S. rollout of HVHDF, which is a standard of care in many markets like Europe. I would say there is not a company in our space that has brought 2 new platforms to market in the U.S. kidney care market that quickly, probably ever. Our rollout of the 5008X continues to progress and in some measures ahead of expectations. by the end of September, we had converted 348 clinics, or 14% of our clinics, by installing approximately 9,000 machines, which is approximately 16% of our install base. This puts us on track to convert 20% of our install base by the end of the year.
In the first nine months, we have performed around 300,000 treatments reaching HVHDF, which is around 1.3% of total treatments, and that has accelerated materially through October. This will be a measure that we track closely. As we approach now more than 500 clinic conversions across the U.S., feedback has been overwhelmingly positive, with providers highlighting improvements in the patient and staff experience, as well as the system's ability to address critical workforce attraction and retention challenges. Our approach is simple: follow the science, continue generating high-quality evidence, and give as many patients as possible access to the therapy with the strongest demonstrated outcomes in randomized studies, and decade-long decision-making by nephrologists globally in choosing this therapy as the standard of care for a predominance of patients. I also want to take the opportunity to update you on certain FDA audits at our facilities in the past months.
We take quality of our products and processes with the utmost of importance and the highest standards. The team has designed plans to strengthen our quality management system and address the findings in the audits. We are actively implementing corrective and preventative actions. For me, personally, I want to ensure that the team first addresses the findings and observations at an accelerated pace, but also in parallel, improves the underlying system and processes so that we do not repeat some of these concerns down the road. Our focus is clearly to ensure the quality, safety, and reliability of the products and therapies that patients and healthcare providers rely on. To conclude this slide, I am also happy to share that we also continue to execute our second EUR 1 billion share buyback program, purchasing 3.4% of share capital as of the end of September.
With that overview, let me hand it over to Martin to walk through the third quarter in much more detail.
Thank you, Shervin, and welcome everyone. I will pick up on slide 8. In the third quarter, group revenue remained broadly stable, supported by organic growth in Care Delivery and partially offset by the anticipated and communicated decline in Value-Based Care revenue, reflecting a change in the risk structure of one contract. Divestitures negatively impacted group revenue development by 30 basis points in the third quarter. Turning to earnings. Operating income, excluding special items, declined by 6% at constant currency, reflecting the anticipated TDAPA reimbursement. We also faced increased inflationary pressures, particularly in Care Enablement. Despite these pressures, our continued focus on underlying profitability improvements supported an operating income margin of 11%. Special items in the third quarter amounted to a net negative EUR 161 million. This includes one-time costs related to the China strategy refinement, which were a bit below the communicated EUR 110 million.
The main components here were the discontinuation of the 4008A production and sales activities, and the exit of the peritoneal dialysis business. Additionally, we continue to execute well on our FME25+ transformation, which resulted in EUR 74 million sustainable savings in the quarter. We invested EUR 54 million one-time cost in the quarter, keeping us fully on track to deliver EUR 250 million in sustainable savings for the full year. These savings are resulting from clinic consolidation in the U.S., manufacturing footprint initiatives, and organizational efficiencies. Let's move to slide 9. Looking at the bridge of operating income, excluding special items. All three segments supported earnings growth, with the strongest contributions from Value-Based Care and Care Delivery. As expected, intersegment eliminations increased as sales of the 5008X CAREsystem into our own U.S. clinics continue to grow.
With the rollout progressing according to plan, we expect this trend to continue for the remainder of the year. Corporate costs increased by EUR 28 million year-over-year. This mainly reflects our planned investments into strategic IT platforms and digital infrastructure, including the transition to SAP S/4HANA. These investments are part of our broader efforts to modernize our systems and improve operational efficiency over time. Foreign currency translation had a positive impact of EUR 4 million this quarter. The average U.S. dollar exchange rate in the third quarter was 115 compared to 117 in the third quarter of 2025. Let me now walk you through the individual segments in more detail, beginning with Care Delivery on slide 10. In the third quarter, Care Delivery revenue increased by 1% at constant currency and 2% organically.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
